Patrick T. Higgins

Mr. Higgins has over 35 years of pharma and biotech experience. The last 25 years in the treatment of liver disease. He most recently was a co-founder and CEO of OnCore Biopharma which merged with Tekmira Inc. in 2015 forming the publicly traded company, Arbutus Biopharma. Arbutus is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). Mr. Higgins previously served as Executive Vice-President, Marketing and Sales of Pharmasset, Inc., from 20007 to 2012, a specialty pharmaceutical company, which researched and developed the cure for hepatitis C virus (HCV), sofosbuvir. Pharmasset was acquired by Gilead Sciences in the largest biotech deal for a non-commercial drug in 2012. From 1995 to 2006, Mr. Higgins was the Vice-President, Sales and Marketing, Virology at Hoffmann-LaRoche, a pharmaceutical company. Prior to Roche, he spent 13 years in various capacities at Schering Plough. Mr. Higgins received his B.A. degree from Villanova University and his M.B.A. degree from Seton Hall University.